欢迎访问《现代生物医学进展》编辑部！

摘要目的：观察利妥昔单抗与CHOP 化疗联合治疗感染乙肝病毒（HBV）的非霍奇金淋巴瘤（NHL）患者的有效性及安全性。方法：选取2010 年6 月至2013 年6 月35 例B 细胞NHL住院患者，分为两组，观察组(n=13)为感染HBV 患者，接受利妥昔单抗 -CHOP 化疗方案；对照组(n=22)为非感染HBV 的患者，单纯接受CHOP 化疗方案，两组治疗4～6 疗程，观察两组患者治疗的疗效及肝功能。结果：观察组完全缓解率（CR率）为76.92％，对照组CR率为40.91％(P＜0.05)，两组差异有统计学意义。观察组肝功能损害I～Ⅱ级发生率为23.07％，对照组肝功能损害I～Ⅱ级发生率18.18％(P>0.05)，观察组毒副反应发生率为30.77%，对照组毒副反应发生率为22.72%（P>0.05），两组在肝功能损害及毒副反应上差异无统计学意义。两组患者HBV 均未再激活。结论：感染HBV的B 细胞NHL患者用R-CHOP 联合化疗方案治疗，以及在化疗时预防性、足疗程的抗病毒治疗，可以减少HBV再激活的发生，并且可以降低肝功损害率。

英文摘要:

ABSTRACT Objective：To observe the effectiveness and safety of the treatment about rituximab combined with CHOP chemotherapy on the non-hodgkin's lymphoma（NHL）patients with HBV infection. Methods：35 B-cell NHL patients（from 2010 to 2013）were divided into two groups: observation group (patients with HBV infection, n=13), They were all treated four to six periods of treatment with R-CHOP regimen, and matched group (patients without HBV infection, n=22), They were all treated four to six periods of treatment with CHOP regimen. Then, the treatment about the effect and liver function were observed. Results：The complete response rate Was 76.92%in the observation group，while 40.91％ in the matched group (P＜0.05). There was statistically significant difference in both groups. The rate of I-II class hepatic damage Was 23.07%in the observation group, and 18.18%in the matched group (P>0.05).The incidence of adverse reaction was 30.77%in the observation group and 22.72%in the matched group (P>0.05). There was no statistically significant difference about hepatic damage or incidence of adverse reaction in both groups.Conclusion： It can reduce the incidence of HBV reactivation and the rate of hepatic damage, While HBV infection of B cell NHL patients use the R-CHOP treatment Combined chemotherapy scheme, and full course of antiviral treatment during the chemotherapy.

查看全文查看/发表评论下载PDF阅读器

关闭